Data on vaccination and exemption rates from school immunization surveys of childcare/preschool, kindergarten, grade 7, grade 11, and college.

Information about school immunization requirements and data

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season.

This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age).
CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here.
• Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors.
• These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US)
• Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*.
• People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.
* DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

Community specific data reports for vaccine administration results, updated weekly, and data from the Public Health (DPH) COVID Community Impact Survey to help target approaches.

Note: As of November 10, 2023, this dataset has been archived. For the current version of this data, please visit: https://health.data.ny.gov/d/gikn-znjh

This dataset reports daily on the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the State to serve as points of distribution.

This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR). County-level vaccination data is based on data reported to NYSIIS and NYC CIR by the providers administering vaccines. Residency is self-reported by the individual being vaccinated. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for county-level statistics. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

This open dataset shows data on Cambridge residents who have received a COVID-19 vaccine at any location (e.g., mass vaccination site, pharmacy, doctor's office). These data come from the Massachusetts Department of Public Health's weekly report on vaccine doses administered by municipality. The report is released on Thursdays. This open dataset includes data going back several weeks and complements another open dataset called "Cambridge Vaccine Demographics," which shows data for the latest week (https://data.cambridgema.gov/Public-Health/Cambridge-Vaccination-Demographics/66td-u88k)

The Moderna and Pfizer vaccines require two doses administered at least 28 days apart in order to be fully vaccinated. The J&J (Janssen) vaccine requires a single dose in order to be fully vaccinated.

The category "Residents Who Received at Least One Dose" reflects the total number of individuals in the fully and partially vaccinated categories. That is, this category comprises individuals who have received one or both doses of the Moderna/Pfizer vaccine or have received the single dose J&J (Janssen) vaccine.

The category "Fully Vaccinated Residents" comprises individuals who have received both doses of the Moderna/ Pfizer vaccine or the single-dose J&J vaccine.

The category "Partially Vaccinated Residents" comprises individuals who have received only the first dose of the Moderna/Pfizer vaccine.

Source: Weekly COVID-19 Municipality Vaccination Report. Massachusetts releases updated data each Thursday at 5 p.m.

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

See the Splitgraph documentation for more information.

Note: As of 1/22/25, this dataset is no longer updated. This dataset reports the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. Currently, three COVID-19 vaccines have been authorized for emergency use by the FDA and approved by New York State's independent Clinical Advisory Task Force: one that was developed by Pfizer and BioNTech, a second that was developed by Moderna and a third that was developed by Janssen/Johnson & Johnson. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the state to serve as points of distribution. This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR).

NYSIIS and CIR are confidential, secure, web-based systems that collect and maintain immunization information in one consolidated record for persons of all ages in NYS governed by Public Health Law 2168. Health care providers are required, by law, to enter all vaccines administered to children up to age 19. Immunizations administered to adults 19 and older may be reported with consent. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration.

Vaccination data by age is based on address data reported to NYSIIS and NYC CIR by the providers administering vaccines. Age is calculated by subtracting the dob from the date of vaccination. Note that COVID-19 vaccine availability greatly expanded for the different age groups over the period of time this dataset covers. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for age group statistics. This dataset is updated weekly.

Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 99.000 % in 2016. This stayed constant from the previous number of 99.000 % for 2015. Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 92.000 % from Dec 1982 (Median) to 2016, with 35 observations. The data reached an all-time high of 99.000 % in 2016 and a record low of 17.000 % in 1982. Morocco MA: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Morocco – Table MA.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Measles, Mumps and Rubella (MMR) Vaccines Market Outlook

The Measles, Mumps, and Rubella (MMR) vaccines market is witnessing a significant expansion, with the global market size estimated at approximately USD 3.2 billion in 2023. It is projected to reach a market size of USD 5.6 billion by 2032, showcasing a compelling compound annual growth rate (CAGR) of 6.5% during the forecast period. One of the primary growth factors propelling this market is the increasing awareness regarding immunization and the global initiatives undertaken by governments and health organizations to eradicate these viral diseases. These efforts have been pivotal in increasing vaccination coverage worldwide, leading to heightened demand for MMR vaccines.

One of the principal growth factors driving the MMR vaccines market is the substantial governmental and non-governmental efforts aimed at eradicating measles, mumps, and rubella globally. Organizations such as the World Health Organization (WHO) and UNICEF have been instrumental in implementing widespread immunization campaigns, especially in underdeveloped and developing regions. These initiatives often involve mass vaccination drives and educational programs to increase awareness about the importance of vaccines, ultimately boosting vaccine uptake. Additionally, government mandates requiring MMR vaccination for school entry in many countries have further increased vaccination rates, contributing significantly to market growth.

Technological advancements in vaccine development and production are another major factor fueling the expansion of the MMR vaccines market. Innovations in biotechnology have led to the creation of more efficient and cost-effective vaccine production processes, thereby increasing the availability of vaccines in various regions. The development of combination vaccines, which include MMR along with other vaccines such as varicella, has also been a noteworthy innovation. These advancements not only enhance the efficiency of immunization programs but also reduce the logistical challenges associated with vaccine storage and distribution. As a result, the improved accessibility and affordability of vaccines are playing a crucial role in market growth.

In recent years, there has been a growing emphasis on addressing vaccine hesitancy, which poses a significant challenge to the widespread adoption of MMR vaccines. Efforts to counter misinformation and increase public trust in vaccines have gained momentum, with health organizations leveraging digital platforms and social media to disseminate accurate information. Educational campaigns focused on the safety and efficacy of vaccines are crucial in overcoming hesitancy and ensuring high vaccination coverage. These initiatives are vital for maintaining the momentum of vaccination programs and achieving global immunization goals, thereby positively impacting the MMR vaccines market.

Regionally, the MMR vaccines market exhibits varying growth patterns, influenced by factors such as healthcare infrastructure, government policies, and public awareness levels. North America continues to hold a significant share of the market, attributed to the region's robust healthcare system and high vaccination coverage. Europe follows closely, benefiting from well-established immunization programs and strong regulatory support. Meanwhile, the Asia Pacific region is experiencing rapid growth, driven by increasing government investments in healthcare and rising public awareness about immunization benefits. As these regions continue to focus on enhancing their healthcare systems and increasing vaccination coverage, the MMR vaccines market is poised for substantial growth.

Vaccine Type Analysis

The MMR vaccines market can be segmented based on vaccine type into live attenuated and inactivated vaccines. Live attenuated vaccines, currently the predominant type, are developed by weakening the viruses, enabling them to provoke a strong immune response without causing the disease. These vaccines have been widely used due to their proven efficacy and long-lasting immunity. The capability of live attenuated vaccines to produce a robust immunogenic response with just a single dose makes them a preferred choice in many immunization programs globally. Moreover, ongoing research aimed at enhancing the stability and potency of these vaccines continues to support their dominance in the market.

Inactivated vaccines, while less common in the market compared to their live attenuated counterparts, represent a significant area of interest and development in the MMR vaccines landscape. These vaccines consist of vi

Access available resources below such as data reports, and Public Health Council presentations.

BackgroundMass vaccination is a cornerstone of public health emergency preparedness and response. However, injudicious placement of vaccination sites can lead to the formation of long waiting lines or queues, which discourages individuals from waiting to be vaccinated and may thus jeopardize the achievement of public health targets. Queueing theory offers a framework for modeling queue formation at vaccination sites and its effect on vaccine uptake.MethodsWe developed an algorithm that integrates queueing theory within a spatial optimization framework to optimize the placement of mass vaccination sites. The algorithm was built and tested using data from a mass dog rabies vaccination campaign in Arequipa, Peru. We compared expected vaccination coverage and losses from queueing (i.e., attrition) for sites optimized with our queue-conscious algorithm to those used in a previous vaccination campaign, as well as to sites obtained from a queue-naïve version of the same algorithm.ResultsSites placed by the queue-conscious algorithm resulted in 9–32% less attrition and 11–12% higher vaccination coverage compared to previously used sites and 9–19% less attrition and 1–2% higher vaccination coverage compared to sites placed by the queue-naïve algorithm. Compared to the queue-naïve algorithm, the queue-conscious algorithm placed more sites in densely populated areas to offset high arrival volumes, thereby reducing losses due to excessive queueing. These results were not sensitive to misspecification of queueing parameters or relaxation of the constant arrival rate assumption.ConclusionOne should consider losses from queueing to optimally place mass vaccination sites, even when empirically derived queueing parameters are not available. Due to the negative impacts of excessive wait times on participant satisfaction, reducing queueing attrition is also expected to yield downstream benefits and improve vaccination coverage in subsequent mass vaccination campaigns.

IntroductionSince 2010, WHO has recommended oral cholera vaccines as an additional strategy for cholera control. During a cholera episode, pregnant women are at high risk of complications, and the risk of fetal death has been reported to be 2–36%. Due to a lack of safety data, pregnant women have been excluded from most cholera vaccination campaigns. In 2012, reactive campaigns using the bivalent killed whole-cell oral cholera vaccine (BivWC), included all people living in the targeted areas aged ≥1 year regardless of pregnancy status, were implemented in Guinea. We aimed to determine whether there was a difference in pregnancy outcomes between vaccinated and non-vaccinated pregnant women.Methods and FindingsFrom 11 November to 4 December 2013, we conducted a retrospective cohort study in Boffa prefecture among women who were pregnant in 2012 during or after the vaccination campaign. The primary outcome was pregnancy loss, as reported by the mother, and fetal malformations, after clinical examination. Primary exposure was the intake of the BivWC vaccine (Shanchol) during pregnancy, as determined by a vaccination card or oral history. We compared the risk of pregnancy loss between vaccinated and non-vaccinated women through binomial regression analysis. A total of 2,494 pregnancies were included in the analysis. The crude incidence of pregnancy loss was 3.7% (95%CI 2.7–4.8) for fetuses exposed to BivWC vaccine and 2.6% (0.7–4.5) for non-exposed fetuses. The incidence of malformation was 0.6% (0.1–1.0) and 1.2% (0.0–2.5) in BivWC-exposed and non-exposed fetuses, respectively. In both crude and adjusted analyses, fetal exposure to BivWC was not significantly associated with pregnancy loss (adjusted risk ratio (aRR = 1.09 [95%CI: 0.5–2.25], p = 0.818) or malformations (aRR = 0.50 [95%CI: 0.13–1.91], p = 0.314).ConclusionsIn this large retrospective cohort study, we found no association between fetal exposure to BivWC and risk of pregnancy loss or malformation. Despite the weaknesses of a retrospective design, we can conclude that if a risk exists, it is very low. Additional prospective studies are warranted to add to the evidence base on OCV use during pregnancy. Pregnant women are particularly vulnerable during cholera episodes and should be included in vaccination campaigns when the risk of cholera is high, such as during outbreaks.

Russia's COVID-19 vaccination rate reached around 129 administered doses per 100 population as of May 26, 2023. The rate of fully vaccinated residents was nearly 55.1 per 100 people. Russia’s COVID-19 vaccination rate was among the lowest in Europe.

COVID-19 vaccination in Russia

The mass vaccination against COVID-19 in Russia started at the beginning of 2021. As of May 2023, over 88 million Russians got at least one vaccine dose. Several regions, including the capital Moscow, required companies in specific industries to vaccinate at least 60 percent of their staff. Such sectors included healthcare, education, retail, and various services, among others. The restrictions were largely lifted in the spring and summer of 2022.

Attitude toward COVID-19 vaccination in Russia

When asked if they planned to get vaccinated against COVID-19, over one-quarter of Russians stated they would definitely or most probably do it, according to a survey from June 2021. Furthermore, nearly one-fifth of respondents reported being vaccinated already at that point. The most common motives to get vaccinated for Russians were to be able to travel without restrictions and not to worry about their health. The main reason behind vaccination hesitancy was a concern about the long-term consequences of COVID-19 vaccines.

COVID-19 vaccination data in Israel processed to show vaccination by age over time. These datasets are derived from publicly available Ministry of Health data, but processed for analytics about uptake in different age groups over time. They cover the mass vaccination campaign for COVID-19 until August 2021. The campaign consisted of the administration of multiple doses of the Pfizer vaccine.

Background: Rabies is a serious yet neglected public health threat in resource-limited communities in Africa, where the virus is maintained in populations of owned, free-roaming domestic dogs. Rabies elimination can be achieved through the mass vaccination of dogs, but maintaining the critical threshold of vaccination coverage for herd immunity in these populations is hampered by their rapid turnover. Knowledge of the population dynamics of free-roaming dog populations can inform effective planning and implementation of mass dog vaccination campaigns to control rabies. Methodology/Principal Findings: We implemented a health and demographic surveillance system in dogs that monitored the entire owned dog population within a defined geographic area in a community in Mpumalanga Province, South Africa. We quantified demographic rates over a 24-month period, from 1st January 2012 through 1st January 2014, and assessed their implications for rabies control by simulating the decline in vaccinat...

Diphtheria Vaccine Market Outlook

The global diphtheria vaccine market size is projected to grow significantly, from USD 2.1 billion in 2023 to approximately USD 3.5 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 5.5%. The primary growth driver for this market is the increasing awareness of diphtheria outbreaks and the critical importance of immunization programs worldwide. Governments and healthcare organizations are increasingly focusing on vaccination as the most effective measure to control and eventually eliminate diphtheria, contributing to the robust market growth.

One of the key growth factors in the diphtheria vaccine market is the rise in government initiatives and funding for immunization programs. Governments across various regions are taking proactive measures to ensure widespread vaccination coverage. This includes subsidizing vaccine costs, conducting mass vaccination drives, and partnering with international health organizations to enhance vaccine accessibility. Additionally, the World Health Organization (WHO) and other global health bodies are playing a crucial role in fostering international cooperation and support, further propelling market growth.

Another significant factor contributing to market expansion is the development of combination vaccines. These vaccines, which offer protection against multiple diseases including diphtheria, tetanus, and pertussis, are gaining popularity due to their convenience and cost-effectiveness. Combination vaccines reduce the number of injections required, thereby improving patient compliance and coverage rates. Innovations in vaccine formulation and delivery, including the advent of needle-free vaccine delivery systems, are also anticipated to support market growth by enhancing the safety and efficiency of immunization processes.

The increasing prevalence of diphtheria in certain regions and the resurgence of the disease in areas with declining vaccination rates further underscore the need for sustained vaccination efforts. Urbanization and global travel are contributing to the spread of infectious diseases, making it crucial to maintain high vaccination coverage. Moreover, the growing awareness among parents and caregivers about the importance of early childhood immunizations is driving the uptake of pediatric vaccines, thus significantly impacting market growth.

In addition to the focus on diphtheria vaccines, there is a growing emphasis on Typhoid Fever Vaccines, particularly in regions where typhoid fever remains a significant public health concern. Typhoid fever, caused by the bacterium Salmonella Typhi, poses a serious threat in areas with poor sanitation and limited access to clean water. Vaccination is a crucial preventive measure, and recent advancements in typhoid vaccines have shown promising results in enhancing immunity and reducing the incidence of the disease. The introduction of conjugate vaccines, which offer longer-lasting protection, is a significant step forward in controlling typhoid fever outbreaks. Efforts to integrate typhoid vaccination into routine immunization schedules are underway, aiming to protect vulnerable populations, especially children, from this potentially life-threatening illness.

Regionally, North America and Europe hold significant shares in the diphtheria vaccine market, driven by well-established healthcare infrastructures and extensive immunization programs. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, supported by increasing government initiatives, rising healthcare spending, and a large population base. Countries like India and China are making substantial investments in healthcare to improve vaccination coverage, which is anticipated to drive regional market growth substantially.

Vaccine Type Analysis

The diphtheria vaccine market can be segmented by vaccine type into DTaP (Diphtheria, Tetanus, and acellular Pertussis), Td (Tetanus and Diphtheria), DT (Diphtheria and Tetanus), and Tdap (Tetanus, Diphtheria, and acellular Pertussis). Among these, DTaP vaccines hold a significant share of the market due to their widespread use in pediatric immunization schedules. These combination vaccines provide comprehensive protection against multiple diseases, making them a preferred choice among healthcare providers and parents. The focus on preventing pertussis alongside diphtheria and tetanus in young children underscores the demand for DTaP vaccines.

BackgroundThe World Health Organization (WHO) recommends oral cholera vaccines (OCVs) as a supplementary tool to conventional prevention of cholera. Dukoral, a killed whole-cell two-dose OCV, was used in a mass vaccination campaign in 2009 in Zanzibar. Public and private costs of illness (COI) due to endemic cholera and costs of the mass vaccination campaign were estimated to assess the cost-effectiveness of OCV for this particular campaign from both the health care provider and the societal perspective. Methodology/Principal FindingsPublic and private COI were obtained from interviews with local experts, with patients from three outbreaks and from reports and record review. Cost data for the vaccination campaign were collected based on actual expenditure and planned budget data. A static cohort of 50,000 individuals was examined, including herd protection. Primary outcome measures were incremental cost-effectiveness ratios (ICER) per death, per case and per disability-adjusted life-year (DALY) averted. One-way sensitivity and threshold analyses were conducted. The ICER was evaluated with regard to WHO criteria for cost-effectiveness. Base-case ICERs were USD 750,000 per death averted, USD 6,000 per case averted and USD 30,000 per DALY averted, without differences between the health care provider and the societal perspective. Threshold analyses using Shanchol and assuming high incidence and case-fatality rate indicated that the purchase price per course would have to be as low as USD 1.2 to render the mass vaccination campaign cost-effective from a health care provider perspective (societal perspective: USD 1.3). Conclusions/SignificanceBased on empirical and site-specific cost and effectiveness data from Zanzibar, the 2009 mass vaccination campaign was cost-ineffective mainly due to the relatively high OCV purchase price and a relatively low incidence. However, mass vaccination campaigns in Zanzibar to control endemic cholera may meet criteria for cost-effectiveness under certain circumstances, especially in high-incidence areas and at OCV prices below USD 1.3.

The mobile vaccination vehicle market is experiencing robust growth, driven by the increasing need for accessible and efficient vaccination programs, particularly in remote and underserved areas. This market's expansion is fueled by several factors, including rising immunization rates globally, the emergence of new vaccine-preventable diseases, and government initiatives promoting public health. The market's convenience and flexibility, especially in managing outbreaks and mass vaccination campaigns, further contribute to its growth trajectory. Let's assume, for illustrative purposes, a 2025 market size of $500 million and a Compound Annual Growth Rate (CAGR) of 15% over the forecast period (2025-2033). This suggests a significant market expansion, reaching an estimated value exceeding $1.7 billion by 2033. This growth, however, may be tempered by factors such as the initial high capital investment required for vehicle acquisition and maintenance, as well as potential regulatory hurdles in certain regions concerning vehicle certifications and operational standards. The success of key players like Timak, RMA Special Vehicles, Beiqi Foton Motor, and FOSUN BEILING hinges on their ability to innovate and adapt to evolving market needs. This includes developing technologically advanced vehicles equipped with sophisticated refrigeration systems, data management capabilities, and user-friendly interfaces. Furthermore, strategic partnerships with healthcare providers and government agencies will be crucial for market penetration and sustained growth. Future market trends indicate a shift towards specialized mobile vaccination units tailored to specific needs, such as mobile cold chain solutions and vehicles equipped for administering multiple vaccines simultaneously. The integration of telemedicine technologies for remote patient monitoring and data analysis will also be a key differentiator in this rapidly evolving landscape.

The following dashboards provide data on contagious respiratory viruses, including acute respiratory diseases, COVID-19, influenza (flu), and respiratory syncytial virus (RSV) in Massachusetts. The data presented here can help track trends in respiratory disease and vaccination activity across Massachusetts.

Abstract

Nigeria implemented series of preventive immunization campaigns to combat measles and yellow fever, two major public health concerns, from October to November 2024. These mass vaccination campaigns aimed to prevent, control, and ultimately eliminate these diseases nationwide. To assess the effectiveness of these efforts, Integrated Post Campaign Coverage Surveys (IPCCS) were conducted after each immunization round to evaluate coverage rates in participating states. This proactive approach is crucial, given Nigeria's history of measles outbreaks and ongoing challenges in achieving optimal vaccination coverage.

Measles: Nigeria's measles vaccination coverage reached 84.2 percent nationwide, but fell short of the 95 percent campaign target threshold set for measles elimination during Supplementary Immunization Activities (SIAs). Vaccination coverage by state ranged between 59 percent in FCT and 97 percent in Ekiti. Children aged 48-59 months had the highest coverage at 85.9 percent whereas those aged 9-11 months had the lowest coverage at 78.2 percent. Urban areas had higher coverage rate of 86.0 percent compared to rural areas at 81.8 percent. No significant difference in vaccination coverage was observed between males and females. The percentage of children that received measles vaccine for the first time during the campaign was 11.7. North Central reported the highest proportion of first-time vaccinations at 16.1 percent, followed by South-South at 12.9 percent, while North East had the lowest at 8.2 percent.

Evidence by card retention, history or recall and finger mark were accessed during the survey. Findings shows that card retention had 44.2 percent, history/recall (38.5 percent) and Finger mark seen (15.8 percent). Card retention across the surveyed states show that respondents in Niger state had highest card retention with 74.0 percent while Ogun state recorded the least card retention with 28.3 percent

Majority of respondents (53.2 percent) learned about the campaign through town criers/ mobilizers/ community health workers. More than 7.0 percent of respondents were not informed of the measles campaign, ranging from 1.9 percent in Ekiti state to 28.9 percent in FCT. The primary reason for non-vaccination was lack of awareness among parents or caregivers (7.0 percent) and 1.3 percent of children were not vaccinated due to religious beliefs.

Yellow Fever: At the aggregate level, the vaccination coverage for Yellow Fever in Borno, Lagos and Yobe states was 67.9 percent which was below the expected 80 percent campaign target threshold. The vaccination coverage by state was 81.6 percent in Yobe, 49.9 percent in Borno state and 62.5 percent in Lagos. Further noticeable disparity in the coverage between urban and rural areas, with urban areas having a higher coverage rate of 72.7 percent compared to 64.7 percent in rural areas. Analysis by age group also shows that coverage among children aged 6-14 years has the highest at 76.8 percent, while the lowest is among adults aged 25-44 years at 57.3 percent. Additionally, vaccination coverage was the same among both males and females at 67.9 percent.

Further analysis on card retention, shows that only 40.0 percent of children who received the vaccination had a vaccination card. Yobe state had the highest proportion of children with vaccination cards at 46.6 percent, while Borno state had the lowest, at 25.9 percent. Evidence of vaccination by finger mark among the targeted States were 10.9 percent in Lagos state, 10.6 percent in Borno state and 3.7 percent in Yobe state.

Majority of respondents learned about the Yellow Fever campaign through town criers /mobilizers/community health workers (31.2 percent), followed by family members (17.5 percent). Among non-vaccinated children, the primary reason was lack of awareness among parents or caregivers (20.0 percent).

Geographic coverage

National Zone State Sector

Analysis unit

Individual

Universe

Individual members 9-59 months for Post Measles and 9-44 months for Post Yellow fever and Measles

Kind of data

Sample survey data [ssd]

Sampling procedure

The frame used for the Integrated Post Campaign Coverage Survey (IPCCS) was the newly digitalize list of enumeration areas for the next National Housing and Population Census. Samples were selected from the frame. However, some parts of Nigeria that were inaccessible due to security reasons were excluded from the sampling frame.

First Stage Selection Forty (40) enumeration areas were selected for coverage in each of the 25 states and FCT-Abuja, thus making 26 strata. A total of 1,028 EAs were selected in all the 25 states and FCT-Abuja.

Second Stage Selection A Systematic random sampling method was used to select households within each EA. A sample of fifteen (15) households were systematically selected per EA for the interview, making a total of 15,600 households across the 25 states and FCT-Abuja.

Third Stage Selection The selection of respondents within each visited household was determined by specific age cohorts and antigen-related criteria.

Measles All children aged 9 to 59 months during the campaign were selected from the household roster and were interviewed about measles vaccination and other additional indicators.

Yellow Fever Individuals from the household roster aged 9 months to 44 years were interviewed about yellow fever vaccination and other related indicators.

Sampling deviation

No Deviations

Mode of data collection

Face-to-face [f2f]

Research instrument

Three structured questionnaires were used for IPCCS of which each consists both household and individual questionnaire.The Questionnaires are -Post Measles Supplementary Immunisation Activity Coverage Survey Questionnaire -Post yellow fever, Supplementary Immunisation Activity Coverage Survey Questionnaire -Post Measles and Yellow fever Supplementary Immunisation Activity Coverage Survey Questionnaire

The household questionnaire was administered in each household, which collected information on Identification and Demographic while the Individual questionnaires are targeted at children 5-59 months for Post measles and 9-44 months for Yellow fever.The information collected includes identification,demographic and immunization.

Cleaning operations

Real - Time data editing took place at different stages throughout the processing which includes: 1) Data editing and cleaning 2) Structure checking and completeness 3) Secondary editing 4) Structural checking of data files

Response rate

The response rate is 100%.

Data appraisal

A series of data quality tables and graphs are available in the report.